Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2004

View Archived Issues

Phase I data on the effects and safety of pemetrexed in breast cancer

New developments at Theratechnologies

BioMarin begins phase II trial of Phenoptin for PKU

U.S. phase IIb results for Technosphere Insulin, phase III begins in Europe

Cerus acquires mesothelin license from Chugai

Matritech refines NMP66 detection for breast cancer

Canadian approval for Cipralex

Centocor licenses rights to ImmunoGen's TAP technology

Vfend approved for candidemia in nonneutropenic patients

NDA submission for premature ejaculation treatment dapoxetine hydrochloride

Myriad Genetics files to begin phase I trial with MPC-2130

Treatment completed in phase III phenserine trial

Tipifarnib shows promise in the treatment of breast cancer

Phase II data on the effects of ZD-6474 in metastatic breast cancer

Ventavis approved for PAH

Update on the cognitive effects and safety profile of TC-1734

Contrast agents claimed by Fuji Photo Film

PTC develops compounds for diseases related to nonsense mutations of mRNA

Antitumor agents reported in patent literature

Yamanouchi team presents series of novel anticoagulants

IgG1 monoclonal antibodies for cancer therapy prepared and tested at Crucell

Finasteride tested to treat alcoholism

Clolar approved for pediatric ALL

Prialt receives FDA approval for severe chronic pain

Synthesis and preclinical efficacy of YM-75440, a novel, orally active squalene synthase inhibitor

Novel derivative of curcumin induces cell cycle arrest of HCT15 colon cancer cells

COX-2-derived prostacyclin is atheroprotective in female mice